跳至主要内容
临床试验/JPRN-jRCT2080220529
JPRN-jRCT2080220529未知2 期

Investigation of the efficacy/safety and clinical dose of TAK-390MR for Erosive Esophagitis - A Phase II/III, Stratified-Randomized, Double-Blind, Parallel-Group, Multicenter Study on Efficacy and Safety of TAK-390MR by Comparison with AG-1749 in Patients with Erosive Esophagitis

Takeda Pharmaceutical Company Limited0 个研究点目标入组 850 人开始时间: 2008年3月14日最近更新:
适应症

试验速览

阶段
2 期
入组人数
850

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1. Subjects endoscopically diagnosed with Los Angeles grade A-D erosive esophagitis
  • 2. Male or female subject at least 20 years of age at time of obtaining consent

排除标准

  • 未提供

研究者

相似试验

进行中(未招募)
1 期
Clinical investigation evaluating safety and efficacy of selective intra-arterial 166Holmium radiation therapy in combination with atezolizumab and bevacizumab for non resectable Hepatocellular carcinoma (HOLMBRAVE)on resectable Hepatocellular carcinoma (HCC)MedDRA version: 21.0Level: LLTClassification code: 10019828Term: Hepatocellular carcinoma non-resectable Class: 10029104
CTIS2024-511538-11-00Institut Gustave Roussy40
已完成
4 期
Effect of Haridradi tail in Acne and Pigmentatio
CTRI/2022/01/039493Ms Ozone Pharmaceuticals Ltd50
进行中(未招募)
1 期
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immundeficiency Diseases (PID)MedDRA version: 9.1 Level: LLT Classification code 10064859 Term: Primary immunodeficiency syndrome
EUCTR2007-002611-27-GBOctapharma AG5
进行中(未招募)
1 期
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immunodeficiency Diseases (PID)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndrome
EUCTR2007-002611-27-FROctapharma AG5
进行中(未招募)
不适用
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immundeficiency Diseases (PID)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndrome
EUCTR2007-002611-27-DEOctapharma AG45